Non-Small Cell Lung Cancer (NSCLC) – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031

Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Report Overview

The total market value for the 15M, which includes both CGTs and established/traditional NSCLC therapies was $30.7 billion in 2021. A high level of unmet need in the second and third line, especially in the PD-L1-negative setting will significantly drive the uptake and usage of novel CGT thereby propelling the market growth.

Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion)

Buy the Full Report to Know More about the Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Forecast, Download a Free Report Sample

The  NSCLC–cell and gene therapies 15-market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.

Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Dynamics

Manufacturing capabilities may cap the number of patients that can be treated, especially for autologous cell therapies, which is having negative impact on the market growth. PHowever, preliminary evidence that TILs are efficacious in NSCLC will open the door to more R&D spending in cell therapies, which will propel the market growth during the forecast period.

Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Analysis by Treatment

• NSCLC presents with niche unmet needs across specific patient populations, which makes an indication-wide impact by CGT therapies unlikely. Products such as TILs are likely to elicit clinical benefit regardless of the previous treatment or the PD-L1 status of the patients, making them excellent candidates for adding another option to the later lines of therapy.
• Gene therapies and oncolytic viruses could synergize with checkpoint inhibitors to tackle primary resistance to immunotherapy, which would significantly change the current treatment paradigm.
• Future treatment to involve re-biopsy and personalization of therapy. Late-stage clinical development of several agents in the 2nd/3rd line in resistant populations.

Buy Full Report for More Insights into the Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Treatment, Download a Free Report Sample

Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Segmentation by Regions

North America had the highest sales in 15MM in the NSCLC – cell and gene therapies 15-market.

A few of the key regions in the market are APAC, Europe, Middle East, and North America.

Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Analysis by Regions, 2021 (%)

Buy Full Report for More Regional Insights into the Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market

Download a Free Report Sample

Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market -Competitive Landscape

Future players only have one or two NSCLC-targeted assets in the pipeline. Moreover, Iovance Biotherapeutics is likely to become one of the next major players in NSCLC if lifileucel is approved by the FDA.

A few of the major players in the non-small cell lung cancer (NSCLC)–cell and gene therapies 15-market are:

• Candel Therapeutics Inc
• NYU Langone Health System
• Pact Pharma Inc
• Fate Therapeutics Inc
• Iovance Biotherapeutics Inc

Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Analysis by Companies

Buy the Full Report to Know More about Companies in the Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market

Download a Free Report Sample

Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Country Outlook (Value, $ Billion, 2021-2031)

• APAC
• Europe
• Middle East
• North America

Scope

The report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.

Key Highlights

• The main drivers of growth include the anticipated approval and launch of 29 pipeline therapies, in addition to label expansions of currently marketed therapies across the 8MM during the forecast period.
• Among the late-stage pipeline products and marketed agents, checkpoint inhibitors and EGFR inhibitors are expected to generate the greatest revenues over the forecast period.
• The most important unmet needs in the NSCLC market include comprehensive molecular testing, novel approaches to primary and acquired resistance, and an improvement in curative therapeutic options

Reasons to Buy

• Obtain cell & gene therapy sales forecasts across multiple regions
• Gain insight into promising early-stage approaches

Our indication-specific forecast models answer questions such as:

• What is the target patient pool for cell & gene therapies in each cancer indication?
• Which patient groups are more likely to receive these therapies?
• What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication
• What is the anticipated breakdown between autologous and allogeneic cell therapies?
• When will cell & gene therapies launch in each market?
• What is the total market value projected for the forecast end, in 2031?